180 related articles for article (PubMed ID: 20645913)
1. PET imaging of multidrug resistance in tumors using 18F-fluoropaclitaxel.
Kurdziel KA; Kiesewetter DO
Curr Top Med Chem; 2010; 10(17):1792-8. PubMed ID: 20645913
[TBL] [Abstract][Full Text] [Related]
2. Imaging multidrug resistance with 4-[18F]fluoropaclitaxel.
Kurdziel KA; Kalen JD; Hirsch JI; Wilson JD; Agarwal R; Barrett D; Bear HD; McCumiskey JF
Nucl Med Biol; 2007 Oct; 34(7):823-31. PubMed ID: 17921033
[TBL] [Abstract][Full Text] [Related]
3. Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]Paclitaxel (FPAC).
Kalen JD; Hirsch JI; Kurdziel KA; Eckelman WC; Kiesewetter DO
Appl Radiat Isot; 2007 Jun; 65(6):696-700. PubMed ID: 17161952
[TBL] [Abstract][Full Text] [Related]
4. Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT.
Kurdziel KA; Kalen JD; Hirsch JI; Wilson JD; Bear HD; Logan J; McCumisky J; Moorman-Sykes K; Adler S; Choyke PL
J Nucl Med; 2011 Sep; 52(9):1339-45. PubMed ID: 21849404
[TBL] [Abstract][Full Text] [Related]
5. Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation.
Kiesewetter DO; Jagoda EM; Kao CH; Ma Y; Ravasi L; Shimoji K; Szajek LP; Eckelman WC
Nucl Med Biol; 2003 Jan; 30(1):11-24. PubMed ID: 12493538
[TBL] [Abstract][Full Text] [Related]
6. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET.
Hsueh WA; Kesner AL; Gangloff A; Pegram MD; Beryt M; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2006 Dec; 47(12):1995-9. PubMed ID: 17138742
[TBL] [Abstract][Full Text] [Related]
7. Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein.
Dörner B; Kuntner C; Bankstahl JP; Wanek T; Bankstahl M; Stanek J; Müllauer J; Bauer F; Mairinger S; Löscher W; Miller DW; Chiba P; Müller M; Erker T; Langer O
Bioorg Med Chem; 2011 Apr; 19(7):2190-8. PubMed ID: 21419632
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
9. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
Schneiderman RS; Shmueli E; Kirson ED; Palti Y
BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723
[TBL] [Abstract][Full Text] [Related]
10. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel.
Gangloff A; Hsueh WA; Kesner AL; Kiesewetter DO; Pio BS; Pegram MD; Beryt M; Townsend A; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Nov; 46(11):1866-71. PubMed ID: 16269601
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
13. In vivo characterization of [
Kannan P; Füredi A; Dizdarevic S; Wanek T; Mairinger S; Collins J; Falls T; van Dam RM; Maheshwari D; Lee JT; Szakács G; Langer O
Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):2026-2035. PubMed ID: 31729540
[TBL] [Abstract][Full Text] [Related]
14. Chemistry and chemical biology of taxane anticancer agents.
Miller ML; Ojima I
Chem Rec; 2001; 1(3):195-211. PubMed ID: 11895119
[TBL] [Abstract][Full Text] [Related]
15. Overcoming multidrug resistance in human cancer cells by natural compounds.
Nabekura T
Toxins (Basel); 2010 Jun; 2(6):1207-24. PubMed ID: 22069634
[TBL] [Abstract][Full Text] [Related]
16. Imaging of multidrug resistance in cancer.
Dizdarevic S; Peters AM
Cancer Imaging; 2011 Mar; 11(1):1-8. PubMed ID: 21362586
[TBL] [Abstract][Full Text] [Related]
17. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE
Oncologist; 2012; 17(4):512. PubMed ID: 22416063
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates.
Kurdziel KA; Kiesewetter DO; Carson RE; Eckelman WC; Herscovitch P
J Nucl Med; 2003 Aug; 44(8):1330-9. PubMed ID: 12902425
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
